Forest's antibiotic ceftaroline positive in Phase III for CABP
This article was originally published in Scrip
Executive Summary
Forest has released positive top-line data of its injectable antibiotic ceftaroline from two pivotal Phase III clinical trials, FOCUS I and FOCUS II, which demonstrate its non-inferiority to ceftriaxone for the treatment of community-acquired bacterial pneumonia (CABP) requiring hospitalisation.